Systemic timolol exposure following topical application to infantile hemangiomas

J Am Acad Dermatol. 2020 Mar;82(3):733-736. doi: 10.1016/j.jaad.2019.02.029. Epub 2019 Feb 18.

Authors

Beth A Drolet¹, Felix Boakye-Agyeman², Barrie Harper², Kristen Holland³, Andrew Lewandowski⁴, Nicole Stefanko³, Chiara Melloni²; Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.)

Collaborators

Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.):
Gary Furda, Danny Benjamin, Edmund Capparelli, Gregory L Kearns, Ian M Paul, Christoph Hornik, Kelly Wade

Affiliations

¹ Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: bdrolet@dermatolgy.wisc.edu.
² Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
³ Medical College of Wisconsin, Milwaukee, Wisconsin.
⁴ The Emmes Corporation, Rockville, Maryland.

PMID: 30790601
DOI: 10.1016/j.jaad.2019.02.029

No abstract available

Publication types

Letter

MeSH terms

Administration, Topical
Adrenergic beta-Antagonists
Hemangioma, Capillary / blood
Hemangioma, Capillary / drug therapy*
Humans
Infant
Timolol / administration & dosage*
Timolol / blood

Substances

Adrenergic beta-Antagonists
Timolol